Research Paper Volume 15, Issue 15 pp 7476—7495
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Figure 6. Immunological implications behind SETBP1 mutations in melanoma. (A) CIBERSORT algorithm revealed the 22 lymphocyte infiltration differences between SETBP1 mutated and wild-type subgroups. (B) Angelova et al. method revealed the 31 lymphocyte infiltration differences between SETBP1 two subgroups. (C) Heatmap illustration of enrichment scores of 14 immune-related molecular signatures according to SETBP1 mutational status. Signaling pathways of (D) T cell receptor signaling pathway, (E) B cell receptor signaling pathway, and (F) chemokine signaling pathway were enriched in SETBP1-MUT melanoma patients. * P < 0.05, ** P < 0.01.